Lars Asphaug

  • Health Economist; PhD
  • +47 99 50 00 63

Publications 2023

Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P et al. (2023)
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951

Publications 2022

Kling J, Asphaug L, Feragen KB (2022)
Cost-effectiveness analysis of a psychosocial web-based intervention for adolescents distressed by a visible difference: Results from a randomized controlled trial in Norway
Scand J Psychol, 64 (3), 268-277
DOI 10.1111/sjop.12885, PubMed 36367227

Publications 2020

Asphaug L, Thiele M, Krag A, Melberg HO (2020)
Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis
Hepatology, 71 (6), 2093-2104
DOI 10.1002/hep.30979, PubMed 31595545

Publications 2019

Asphaug L, Melberg HO (2019)
The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway
MDM Policy Pract, 4 (1), 2381468318821103
DOI 10.1177/2381468318821103, PubMed 30746499

Page visits: 3062